Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 163Endometrial Neoplasms 13Ovarian Neoplasms 12Fallopian Tube Neoplasms 5Recurrence 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Intraductal, Noninfiltrating 4Triple Negative Breast Neoplasms 3Breast Diseases 3Breast Cancer Metastatic 3Prostatic Neoplasms 2Leiomyosarcoma 2Carcinoma, Lobular 2Advanced Breast Cancer 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Small Cell Lung Carcinoma 1Polycystic Ovary Syndrome 1Pathologic Complete Response 1Pancreatic Neoplasms 1Pain 1Osteoporosis 1Neoplastic Cells, Circulating 1Neoadjuvant Operable Breast Cancer 1Multiple Endocrine Neoplasia Type 1 1Medullary cystic kidney disease 1 1Lymphangioleiomyomatosis 1

Interventions

Tablets 1Letrozole 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Highly Endocrine Responsive Operable Breast Cancer × Letrozole × Clear all
NCT03397537 2018-01-17

Neoadjuvant Endocrine Therapy in Breast Cancer

Guangdong Provincial People's Hospital

Phase 2 Completed
46 enrolled
Breast

Highly Endocrine Responsive Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡